<DOC>
	<DOCNO>NCT02269163</DOCNO>
	<brief_summary>A Phase 3 , Multinational , Multicenter , Open-Label Study Safety , Tolerability , Efficacy , Pharmacokinetics ProMetic BioTherapeutics Immune Globulin Intravenous ( Human ) 10 % Adults Children Primary Immunodeficiency Diseases ( PIDD ) ass tolerability , safety , efficacy pharmacokinetics ProMetic 's IGIV subject PIDD . IGIV intend treatment child adults Primary Immunodeficiency Diseases ( PIDD ) require IgG ( Immunoglobulin G ) replacement therapy</brief_summary>
	<brief_title>A Phase 3 , Multinational , Multicenter , Open-Label Study ProMetic BioTherapeutics IVIG</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>1 . Subject male female age 2 80 year Screening . For Russian site , subject 18 year age old , treat commercially license immune globulin product enrol . For Cohort 1 , subject age ≥17 80 year . For Cohort 2 , subject age 2 &lt; 17 year 2 . Subject parent ( ) /legal guardian give write informed consent/assent ( applicable ) . Pediatric subject define 2 17 year age study entry require assent form appropriate . 3 . Subject parent ( ) /legal guardian agrees comply requirement protocol . 4 . Female subject childbearing potential must negative urine pregnancy test document visit receive first infusion IMP must agree employ adequate birth control measure , determine IRB/IEC , duration study . 5 . The subject must establish one follow three diagnosis ( isolated PIDD type exclude ) : Common variable immunodeficiency ( CVID ) Xlinked agammaglobulinemia ( XLA ) HyperIgM syndrome document low IgG level ( &lt; 4.5 mg/mL [ 450 mg/dL ] ) . 6 . Subjects must treat stable dose immune globulin administer intravenously ( IGIV ) subcutaneously ( IGSC ) , define . For IGIV , stable dose define administration dose 200800 mg/kg 25 % change least 3 consecutive treatment 21day ( ±4 day ) 28day ( ±4 day ) dose interval . For IGSC , stable dose define administration dose 300900 mg/kg/month IV ( Subcutaneous equivalent ) , regardless dose schedule , 25 % change least 12 week . 7 . Subjects receive IGSC enter study must receive least one previous document IGIV infusion without associate serious adverse event . 8 . Documented trough steady state level Subjects receive IGIV enter study least 2 documented serum IgG trough level ≥ 5 mg/ mL measure prior 6 month . One serum IgG level Screening . Subjects receive IGSC least 2 documented serum IgG steady state level ≥ 5 mg/mL prior 24 week . One serum IgG level Screening . 9 . Authorization access personal health information . 1 . Subject secondary immunodeficiency diagnose dysgammaglobulinemia isolated IgG subclass deficiency . 2 . Subject ever history severe anaphylactic anaphylactoid reaction immunoglobulin blood product . 3 . Subject known history immunoglobulin A ( IgA ) deficiency know antiIgA antibody . ( Note subject IgA deficiency without know antibody IgA may enrol . ) 4 . Subject thrombotic event , deep vein thrombosis , myocardial infarction , cerebrovascular accident , pulmonary embolism , time . 5 . Subject receive blood product except IGIV , IGSC , albumin within previous 12 month . 6 . Subject participate another study ( except IGIV , IGSC study ) within previous 4 week . 7 . Subject cancer past 5 year , except basal cell squamous cell cancer skin . 8 . Subject current prior diagnosis malignancy lymphoid cell lymphocytic leukemia , nonHodgkin 's lymphoma , immunodeficiency thymoma . 9 . Subject know hypoalbuminemia ( &lt; 3 gm/dL ) , proteinlosing enteropathy , nephrotic syndrome . 10 . Subject document active infection within 7 day prior Screening , subject continuous prophylactic antibiotic . Subjects receive course antibiotic treatment recent bacterial infection , control , enrol study . 11 . Subject positive human immunodeficiency virus ( HIV ) 1 HIV2 . 12 . Subject positive hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) nucleic acid test ( NAT ) perform either qualitative quantitative polymerase chain reaction ( PCR ) past 12 month . 13 . Subject level alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 time upper limit normal ( ULN ) . 14 . Subject serum creatinine &gt; 1.5 time ULN severe chronic condition renal failure proteinuria . 15 . Subject anemia hemoglobin level ≤8 g/dL . 16 . Subject severe neutropenia neutrophil count ≤1000 per mm3 lymphopenia &lt; 500 per/ mm3 . 17 . Subject take prednisone dose ≥0.15 mg/kg/day . ( Topical steroid skin condition , steroid eye drop , chronic use inhale steroid asthma , intranasal steroid rhinitis allow . ) Exception : A brief course systemic steroid threshold ( i.e. , steroid burst ) allow treatment shortterm condition asthma exacerbation poison ivy exposure . 18 . Subject receive immunosuppressive drug chemotherapy . 19 . Subject know atrial fibrillation require anticoagulant therapy ; congestive heart failure ( New York Heart Association Class III/IV ) ; cardiomyopathy ; cardiac arrhythmia associate thromboembolic event , unstable advanced ischemic heart disease , hyperviscosity . 20 . Subject know decreased Protein C and/or Protein S level . 21 . Subject positive antibody β2GPI and/or β2GPIDI Screening . 22 . Female subject pregnant , breastfeeding , plan pregnancy course study . 23 . A history epilepsy multiple episode migraine ( define least one episode within 6 month enrolment ) completely control medication , condition likely interfere evaluation IMP satisfactory conduct study Investigator 's opinion .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>